News

BioPorto Third Quarter Financial Overview: Growth in NGAL Sales

BioPorto Third Quarter Financial Overview: Growth in NGAL Sales

BioPorto Shows Strong Performance in Q3 Financial Results

BioPorto A/S, a leading in vitro diagnostics company, recently shared its interim financial results, marking notable progress through the third quarter. The company continues to emphasize its mission to enhance kidney health with innovative products, particularly in light of their growing NGAL sales.

Overview of Financial Growth

The latest report showcases that revenue for the third quarter of 2025 reached DKK 10.4 million. This figure reflects a 7% growth compared to the same time last year, displaying a healthy upward trend in the company’s sales. At constant exchange rates, the increase jumps to 10%. For the first nine months of 2025, BioPorto recorded total revenue of DKK 28.7 million, indicating a modest 1% increase year-over-year.

NGAL Sales Performance

In terms of NGAL, the heart of BioPorto’s operations, sales hit DKK 7.2 million in the third quarter. This represents a 5% growth compared to the previous year, with an impressive 10% growth when adjusted for exchange rates. As the company moves forward, NGAL continues to be pivotal in its business strategy, aiding in the diagnosis of acute kidney injury (AKI).

Strategic Milestones and New Developments

BioPorto has adopted a renewed strategy called “Forward,” focusing on market adoption and expanding its addressable market. A significant accomplishment occurred when the first ProNephro AKI™ (NGAL) order was successfully delivered to the U.S. market, marking a crucial step in the company's commercial rollout.

Clinical Trials and FDA Submissions

By the end of October 2025, patient enrollment in a pivotal clinical study was successfully completed. BioPorto has announced its intention to engage with the FDA for a pre-submission meeting, ensuring that its clinical validation study aligns closely with regulatory expectations. Initially projected for completion by the end of 2026, the submission timeframe has now been adjusted to the first half of 2027. This timeline underscores the company’s commitment to the highest quality research.

Financial Projections and Investor Insights

BioPorto’s financial outlook remains optimistic. The company has set a full-year revenue target between DKK 40-45 million, alongside an expected adjusted EBITDA loss ranging between DKK 75-80 million for 2025. The robust financial foundation is supported by a recent fully subscribed private placement that generated approximately DKK 43 million, bolstering the company's ambitions for positive cash flow.

Leadership Insights

Carsten Buhl, BioPorto’s CEO, has expressed confidence in the company’s trajectory, highlighting the importance of quality data analysis for successful product validation. He emphasized that the strategy aligns with efforts to transform kidney care worldwide, assuring stakeholders of the company’s dedication to innovation and improving patient outcomes.

About BioPorto and Its Mission

BioPorto is dedicated to enhancing the quality of life for patients through actionable kidney biomarkers that help clinicians in patient management. Their flagship product, the NGAL test, plays a crucial role in early detection of acute kidney injury, enabling timely interventions that can significantly impact patient care.

The company operates on a global scale, with facilities situated in Copenhagen and Boston. BioPorto's shares are publicly traded on the Nasdaq Copenhagen exchange under the ticker CPH:BIOPOR, making it accessible to a broad base of investors eager to support advancements in healthcare.

Frequently Asked Questions

What is BioPorto's main product focus?

BioPorto focuses on in vitro diagnostics, particularly through its NGAL biomarkers used for assessing kidney health and managing acute kidney injury.

What are the recent financial achievements of BioPorto?

For the third quarter of 2025, BioPorto reported revenues of DKK 10.4 million, showing a 7% year-over-year increase.

When does BioPorto expect to submit to the FDA?

BioPorto plans to submit its clinical validation data to the FDA in the first half of 2027 after thorough data analysis.

How is BioPorto supporting its financial growth?

The company recently completed a private placement that raised approximately DKK 43 million to support its operations and growth plans.

Where are BioPorto's operational facilities located?

BioPorto has operational facilities in both Copenhagen, Denmark, and Boston, Massachusetts, USA.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 75

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Africa Tech Awards Put Infrastructure Back in Focus

Updated Category News Views 97

Twelve trophies in Cape Town tell a more useful story than most glossy technology forecasts ever manage to. The Africa Tech Festival Awards 2026, announced on November 19 during the event's 29th annual gathering, cut across connectivity, telecoms, AI, cybersecurity, data centres, cloud, fintech, startups and enterprise transformation. That breadth matters. Africa's...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 48

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 148

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 78

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 53

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 172

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 134

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 91

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading

Top 5 Most Recently Viewed Articles

Transparency in Securities Disclosure: Learning Technologies' Interest

Updated Category News Views 111

Key Information About Securities Disclosure In the evolving landscape of financial regulations, transparency stands as a foundational requirement for public companies. One of the pivotal rules governing such disclosures is laid out in Rule 8.3 of the Takeover Code. This rule mandates that entities or individuals with interests in relevant securities of 1% or more must...

Continue Reading
Chart Industries Inc. Reports Impressive Q2 Performance

Updated Category News Views 115

Exceptional Financial Growth in Q2 Chart Industries, Inc. (NASDAQ: GTLS) shared its financial results for the second quarter. The company witnessed notable growth compared to the previous year's quarter, marking a significant trajectory in its market position. Quarterly Highlights In the second quarter, Chart Industries recorded orders totaling $1.50 billion, representing...

Continue Reading
Marine Lubricants Market Growth Forecast: USD 7.8 Billion

Updated Category News Views 70

Overview of the Marine Lubricants Market The marine lubricants market is steadily growing, with forecasts estimating its value will reach an impressive USD 7.8 billion by 2032. This growth is driven by a compound annual growth rate (CAGR) of 2.07% during the period from 2024 to 2032. Key Drivers Behind Market Growth One of the main factors fueling this market's growth is...

Continue Reading
Celebrating Diversity in Arbitration: CCA’s New Class Announced

Updated Category News Views 185

Celebrating Diversity with New CCA Associates Class The College of Commercial Arbitrators (CCA) is thrilled to introduce the new class of Associates for the 2025–2027 mentorship program. This initiative, started in 2022, highlights the CCA's commitment to nurturing emerging talent in the field of commercial arbitration, particularly from underrepresented backgrounds. By...

Continue Reading
Big Bronze Unveils Final K9 Statue to Honor Veterans

Updated Category News Views 211

Big Bronze Completes Veteran's Memorial with Final K9 Statue Big Bronze, renowned for its exquisite bronze sculptures, is thrilled to share the news of completing an important project at Veterans Memorial Park. This milestone marks the addition of the fourth and final statue in a series designed to honor the sacrifices of U.S. veterans. A Tribute to Valor and Sacrifice...

Continue Reading